Advice
In the absence of a submission from the holder of the marketing authorisation:
denosumab 60mg solution for injection in pre-filled syringe (Prolia): Is not recommended for use in NHSScotland.
Indication under review: bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- denosumab (Prolia)
- SMC ID:
- 670/10
- Indication:
- Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 December 2010